Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.78 - $10.12 $54,810 - $146,740
-14,500 Reduced 43.94%
18,500 $91,000
Q2 2024

Aug 14, 2024

SELL
$4.39 - $5.43 $6,584 - $8,145
-1,500 Reduced 4.35%
33,000 $147,000
Q1 2024

May 15, 2024

BUY
$4.82 - $6.93 $31,330 - $45,045
6,500 Added 23.21%
34,500 $179,000
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $11,823 - $17,367
2,100 Added 8.11%
28,000 $189,000
Q3 2023

Nov 15, 2023

BUY
$6.71 - $11.83 $67,771 - $119,483
10,100 Added 63.92%
25,900 $173,000
Q2 2023

Aug 23, 2023

BUY
$11.12 - $22.2 $175,696 - $350,760
15,800 New
15,800 $181,000
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $18,678 - $28,094
-1,100 Reduced 6.21%
16,600 $297,000
Q2 2022

Aug 15, 2022

BUY
$13.15 - $20.45 $11,835 - $18,405
900 Added 5.36%
17,700 $327,000
Q1 2022

May 16, 2022

BUY
$14.54 - $21.5 $244,272 - $361,200
16,800 New
16,800 $300,000
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $208,471 - $370,903
-10,300 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$26.01 - $38.22 $80,631 - $118,482
3,100 Added 43.06%
10,300 $325,000
Q2 2021

Aug 06, 2021

SELL
$29.97 - $37.17 $152,847 - $189,567
-5,100 Reduced 41.46%
7,200 $225,000
Q1 2021

May 14, 2021

BUY
$29.24 - $42.03 $122,808 - $176,526
4,200 Added 51.85%
12,300 $409,000
Q4 2020

Feb 12, 2021

SELL
$35.35 - $50.67 $49,490 - $70,938
-1,400 Reduced 14.74%
8,100 $301,000
Q3 2020

Nov 13, 2020

BUY
$35.98 - $47.66 $133,126 - $176,342
3,700 Added 63.79%
9,500 $342,000
Q2 2020

Aug 13, 2020

BUY
$45.06 - $67.74 $58,578 - $88,062
1,300 Added 28.89%
5,800 $265,000
Q1 2020

May 11, 2020

BUY
$40.01 - $73.97 $180,045 - $332,865
4,500 New
4,500 $203,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $333M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.